These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 8102399)

  • 1. Olsalazine versus sulfasalazine in mild to moderate childhood ulcerative colitis: results of the Pediatric Gastroenterology Collaborative Research Group Clinical Trial.
    Ferry GD; Kirschner BS; Grand RJ; Issenman RM; Griffiths AM; Vanderhoof JA; Fiedorek SC; Winter HS; Hassall EG; Watkins JB
    J Pediatr Gastroenterol Nutr; 1993 Jul; 17(1):32-8. PubMed ID: 8102399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relapse-preventing effect and safety of sulfasalazine and olsalazine in patients with ulcerative colitis in remission: a prospective, double-blind, randomized multicenter study. The Ulcerative Colitis Multicenter Study Group.
    Rijk MC; van Lier HJ; van Tongeren JH
    Am J Gastroenterol; 1992 Apr; 87(4):438-42. PubMed ID: 1348159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Olsalazine sodium in the treatment of ulcerative colitis among patients intolerant of sulfasalazine. A prospective, randomized, placebo-controlled, double-blind, dose-ranging clinical trial.
    Meyers S; Sachar DB; Present DH; Janowitz HD
    Gastroenterology; 1987 Dec; 93(6):1255-62. PubMed ID: 2890550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of ulcerative colitis with olsalazine and sulphasalazine: efficacy and side-effects.
    Ewe K; Eckardt V; Kanzler G
    Scand J Gastroenterol Suppl; 1988; 148():70-5. PubMed ID: 2906479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Olsalazine versus sulphasalazine for relapse prevention in ulcerative colitis: a multicenter study.
    Nilsson A; Danielsson A; Löfberg R; Benno P; Bergman L; Fausa O; Florholmen J; Karvonen AL; Kildebo S; Kollberg B
    Am J Gastroenterol; 1995 Mar; 90(3):381-7. PubMed ID: 7872274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Double-blind dose-finding study of olsalazine versus sulphasalazine as maintenance therapy for ulcerative colitis.
    Kruis W; Judmaier G; Kayasseh L; Stolte M; Theuer D; Scheurlen C; Hentschel E; Kratochvil P
    Eur J Gastroenterol Hepatol; 1995 May; 7(5):391-6. PubMed ID: 7614099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controlled trial comparing olsalazine and sulphasalazine for maintenance treatment of ulcerative colitis.
    Jewell DP; Ireland A
    Scand J Gastroenterol Suppl; 1988; 148():45-7. PubMed ID: 2906477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Double-blind comparison of olsalazine and sulphasalazine in active ulcerative colitis.
    Willoughby CP; Cowan RE; Gould SR; Machell RJ; Stewart JB
    Scand J Gastroenterol Suppl; 1988; 148():40-4. PubMed ID: 2906476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double blind study.
    Rao SS; Dundas SA; Holdsworth CD; Cann PA; Palmer KR; Corbett CL
    Gut; 1989 May; 30(5):675-9. PubMed ID: 2567266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different therapy for different types of ulcerative colitis in China.
    Jiang XL; Cui HF
    World J Gastroenterol; 2004 May; 10(10):1513-20. PubMed ID: 15133864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylactic effects of olsalazine v sulphasalazine during 12 months maintenance treatment of ulcerative colitis. The Danish Olsalazine Study Group.
    Kiilerich S; Ladefoged K; Rannem T; Ranløv PJ
    Gut; 1992 Feb; 33(2):252-5. PubMed ID: 1347280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olsalazine in the treatment of ulcerative colitis among patients intolerant of sulphasalazine: a prospective, randomized, placebo-controlled, double-blind, dose-ranging clinical trial.
    Meyers S; Sachar DB; Present DH; Janowitz HD
    Scand J Gastroenterol Suppl; 1988; 148():29-37. PubMed ID: 2906474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double-blind placebo-controlled study of olsalazine in the treatment of ulcerative colitis.
    Zinberg J; Molinas S; Das KM
    Am J Gastroenterol; 1990 May; 85(5):562-6. PubMed ID: 2337059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis.
    Kruis W; Brandes JW; Schreiber S; Theuer D; Krakamp B; Schütz E; Otto P; Lorenz-Mayer H; Ewe K; Judmaier G
    Aliment Pharmacol Ther; 1998 Aug; 12(8):707-15. PubMed ID: 9726382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pancreatitis associated with olsalazine and sulfasalazine in children with ulcerative colitis.
    Garau P; Orenstein SR; Neigut DA; Kocoshis SA
    J Pediatr Gastroenterol Nutr; 1994 May; 18(4):481-5. PubMed ID: 7520936
    [No Abstract]   [Full Text] [Related]  

  • 16. Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis.
    Ireland A; Mason CH; Jewell DP
    Gut; 1988 Jun; 29(6):835-7. PubMed ID: 2898422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Olsalazine in maintenance of clinical remission in patients with ulcerative colitis.
    Wright JP; O'Keefe EA; Cuming L; Jaskiewicz K
    Dig Dis Sci; 1993 Oct; 38(10):1837-42. PubMed ID: 8404404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: a randomised double blind trial.
    Feurle GE; Theuer D; Velasco S; Barry BA; Wördehoff D; Sommer A; Jantschek G; Kruis W
    Gut; 1989 Oct; 30(10):1354-61. PubMed ID: 2684804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A meta-analysis of the efficacy of sulfasalazine in comparison with 5-aminosalicylates in the induction of improvement and maintenance of remission in patients with ulcerative colitis.
    Nikfar S; Rahimi R; Rezaie A; Abdollahi M
    Dig Dis Sci; 2009 Jun; 54(6):1157-70. PubMed ID: 18770034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mesalamine and olsalazine: 5-aminosalicylic acid agents for the treatment of inflammatory bowel disease.
    Segars LW; Gales BJ
    Clin Pharm; 1992 Jun; 11(6):514-28. PubMed ID: 1600685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.